hVIVO (CHIMagents) is a company of experienced and committed individuals building a portfolio of challenge agents to be used in controlled human infection studies. Controlled human infection studies are becoming more-and-more important for pharmaceutical companies to take Go/No-Go decisions in the development track of potential vaccines and anti-viral drugs. Together with Key Opinion Leaders and Subject Matter Experts in the field, hVIVO identifies relevant strains and guides development and manufacturing of new challenge agents according to (c)GMP to ensure they are authorised for use in clinical trials in the EU and US.
